FranΓ§aisπ See the interactive version (live chart) β
For Phibro Animal Health, we replayed every analyst price target of the past 12 months and measured the real outcome: 50% were profitable, average return +10% (30 calls). At 3 months: +2% average return (44% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Barclays | 12 | 33% | -5% |
The analyst consensus on Phibro Animal Health (PAHC) is "Hold" (1 bullish, 1 bearish calls over 12 months). This is not advice: historically, 50% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $44.00 (+21% vs $36.35), ranging from $44.00 to $44.00 (1 analysts).
Over 1 year, 50% of analyst targets on Phibro Animal Health were profitable, for an average return of +10% (across 30 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $44.00 within 12 months, i.e. +21% vs the current price. The most bullish targets $44.00, the most cautious $44.00.
Note: analyst targets are 12-month (median $44.00, +21%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (50%), and the stock's past trajectory.
Detailed valuation data for Phibro Animal Health is available in the interactive analysis.
π See the full interactive analysis of Phibro Animal Health β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.